Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough
| Autor: | Laura J. Miske, Howard B. Panitch, Eileen M. Hickey, Susan M. Kolb, Daniel J. Weiner |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Weakness Neuromuscular disease Adolescent medicine.medical_treatment Atelectasis Critical Care and Intensive Care Medicine Muscular Atrophy Spinal Positive-Pressure Respiration medicine Humans Myopathy Child Retrospective Studies Mechanical ventilation business.industry Infant Insufflation Neuromuscular Diseases Pneumonia Airway obstruction medicine.disease Surgery Muscular Dystrophy Duchenne Cough Exhalation Anesthesia Child Preschool Female Exsufflation medicine.symptom Safety Cardiology and Cardiovascular Medicine business |
| Zdroj: | Chest. 125(4) |
| ISSN: | 0012-3692 |
| Popis: | Background Impaired cough secondary to weakness from neuromuscular disease (NMD) can cause serious respiratory complications, including atelectasis, pneumonia, small airway obstruction, and acidosis. The mechanical in-exsufflator (MI-E) delivers a positive-pressure insufflation followed by an expulsive exsufflation, thereby simulating a normal cough. Use of the MI-E in adults with impaired cough results in improved cough flows and enhanced airway clearance. However, only limited reports of MI-E use in children exist. Objective To determine the safety, tolerance, and effectiveness of the MI-E in a pediatric population. Method Retrospective medical record review. Participants Sixty-two patients (34 male patients) observed in a pediatric pulmonary program with NMD and impaired cough in whom MI-E therapy was initiated. Median age at initiation of MI-E use was 11.3 years (range, 3 months to 28.6 years). Diagnoses included the following: Duchenne muscular dystrophy (17 patients); spinal muscular atrophy, types I and II (21 patients); myopathy (12 patients); other nonspecific NMD (12 patients). Mechanical ventilation via tracheostomy was used in 29 patients, and 25 patients used noninvasive ventilation. Results The median duration of use was 13.4 months (range, 0.5 to 45.5 months). One infant died before using MI-E at home. Five patients chose not to continue MI-E therapy. Complications were reported in two patients, but ultimately they used the MI-E device. Chronic atelectasis resolved in four patients after beginning MI-E therapy, and five patients experienced a reduction in the frequency of pneumonias. Conclusion In 90% of our study population, the use of an MI-E was safe, well-tolerated, and effective in preventing pulmonary complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|